×

J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences

By Thomson Reuters Nov 16, 2026 | 7:15 AM

Nov 16 (Reuters) – Johnson & Johnson said on Monday it ​had agreed ‌to buy Texas-based biotech Ollin Biosciences, expanding its pipeline of ‌eye ​disease ⁠therapies.

Johnson & Johnson will ⁠acquire Ollin for $2.2 billion upfront, with the potential for ​regulatory and commercial milestone payments ⁠of up ⁠to about $1.13 ​billion, the drugmaker said.

Ollin, ​backed by investment firms ‌ARCH Venture Partners and Mubadala Capital, was ⁠established in 2023 to develop treatments for vision-threatening ⁠diseases.

The ‌deal is ⁠expected to close ​before ‌the end of ​2026.

(Reporting ⁠by Sneha S K in Bengaluru; Editing by Anil D’Silva and Joyjeet ​Das)